Back grey_arrow_rt.gif
 
Fatty Liver, NASH, NAFLD
 
NASH - Nonalcoholic steatohepatitis NAFLD -
nonalcoholic fatty liver disease
 
null.gif
 
 
  1. 2nd New Fatty Liver Drug Pegozafermin in Phase 3 - (08/04/24)
     
  2. Phase 3 Efuxifermin Fatty Liver/MASH Trial Ongoing; EASL 96 weeks HARMONY phase 2b study Results - (08/04/24)
     
  3. Steatotic liver disease and HIV: an agenda for 2030: 'PWH should be screened for fatty liver, steatosis' - (07/10/24)
     
  4. EASL: Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH - (06/18/24)
     
  5. EASL: Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis - (06/12/24)
     
  6. EASL: Development and Validation of CLDQ-MASH: A Disease-specific Health-related Quality of Life Instrument for Patients with MASH - (06/12/24)
     
  7. EASL: Results from a phase 2a randomized trial with the transglutaminase 2 inhibitor ZED1227 in patients with MASLD - (06/12/24)
     
  8. EASL: Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis - (06/12/24)
     
  9. EASL: Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week international, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis - (06/12/24)
     
  10. EASL: The economic burden of MASLD and MASH in US, Japan, Germany......$300 billion+, $62 B direct healthcare costs, $250 billion productivity loss in USA - (06/12/24)
     
  11. EASL: Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial - (06/12/24)
     
  12. EASL: Structured exercise plus mediterranean diet intervention in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a randomized controlled trial. The EHmet-DIA study - (06/12/24)
     
  13. EASL: Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial - (06/12/24)
     
  14. EASL: Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial - (06/12/24)
     
  15. EASL: Characteristics and risk of major adverse liver outcomes and major cardiovascular events among Swedish patients with diagnosed and high risk of metabolic dysfunction-associated steatohepatitis-a REVEAL-MASH study High Fibrotic NASH Index Predicts 20% 10-Year Cardio Event Risk - Mark Mascolini (06/12/24)
     
  16. EASL: Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography - a multicenter cohort study of 10,920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) - (06/12/24)
     
  17. A global action agenda for turning the tide on fatty liver disease - (05/30/24)
     
  18. Opportunities and challenges following approval of resmetirom for MASH liver disease - (05/30/24)
     
  19. CROI: Summary from CROI 2024 for HIV and liver disease - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/25/24)
     
  20. Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis - (03/20/24)
     
  21. CROI: Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study - (03/12/24)
     
  22. CROI: Semaglutide Lowers Some Inflammation Markers in HIV Lipohypertrophy - Mark Mascolini (03/12/24)
     
  23. CROI: Low-Dose Semaglutide Cuts Weight, Triglycerides, and Glucose in HIV MASLD Group - Mark Mascolini (03/12/24)
     
  24. CROI: Race/Ethnicity and Risk of NAFLD and Clinically Significant Fibrosis in Persons Living with HIV - (03/12/24)
     
  25. CROI: NAFLD and Advanced Fibrosis Are Common in Adults With HIV and Associated With Unique Histology - (03/12/24)
     
  26. Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine - (02/16/24)
     
  27. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis - (02/16/24)
     
  28. Global Prevalence Increased by 50% - The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review - (01/29/24)
     
  29. AASLD: Food Insecurity, Low Income Drive MASLD in US Adolescents - Mark Mascolini (11/21/23)
     
  30. AASLD: Fraction of Liver Injuries From Dietary Supplements Rising in US - Mark Mascolini (11/21/23)
     
  31. AASLD: MUSCLE FAT INFILTRATION IS ELEVATED IN PREFRAIL AND MODERATELY PHYSICALLY IMPAIRED PATIENTS - INTERIM RESULTS FROM THE PROSPECTIVE MULTI-CENTER CIRRHOSIS COHORT STUDY ACCESS-ESLD - (11/21/23)
     
  32. AASLD: Liver Damage & COVID Vaccines - (11/20/23)
     
  33. AASLD: Lean Mash Means Higher Mortality-But Less Decompensation-in US Veterans - Mark Mascolini (11/20/23)
     
  34. AASLD: Aldafermin Meets 48-Week Primary and Secondary Endpoints for MASH Cirrhosis - Mark Mascolini (11/20/23)
     
  35. AASLD: Empagliflozin (SGLT-2) Cuts Liver Fat in People With T2DM and Obese People Without T2DM - Mark Mascolini - (11/20/23)
     
  36. AASLD: Saroglitazar Lowers ALT and Triglycerides, Reducing Liver Stiffness in MASH - Mark Mascolini (11/20/23)
     
  37. AASLD: TRIPLE HORMONE RECEPTOR AGONIST RETATRUTIDE RESOLVES STEATOSIS IN >85 % OF SUBJECTS WITH MASLD AND OBESITY IN ASSOCIATION WITH IMPROVED METABOLIC HEALTH - (11/20/23)
     
  38. AASLD: Lubiprostone reduces fat content on MRI-PDFF in patients with MASLD: A 48-week randomized clinical trial - (11/20/23)
     
  39. AASLD: Topline Results from a 12-Week Phase 2a Trial (DUET) Evaluating TERN-501, a Highly Selective Thyroid Hormone Receptor (THR) β Agonist, Either as Monotherapy or in Combination with TERN-101, a Nonsteroidal Farnesoid X Receptor (FXR) Agonist, Demonstrated Significant Reductions in MR-Based Liver Fat Content and Fibroinflammation in Patients with Presumed MASH - (11/20/23)
     
  40. AASLD: Efruxifermin in Compensated Cirrhosis due to NASH/MASH: Results from a Randomized, Double-blind, Placebo-controlled, Phase 2b Trial (SYMMETRY) - (11/20/23)
     
  41. AASLD: Six-Year Follow-up of Managing Predominantly Hispanic Patients with Significant Steatosis at a Primary Care Clinic - (11/20/23)
     
  42. AASLD: Digital image quantification of the antifibrotic effect of semaglutide and the impact of liver fat in non-alcoholic steatohepatitis - (11/20/23)
     
  43. AASLD: Maximizing the Benefits of Statin Therapy for Liver Disease Prevention - Targeting Patients with unmet Statin Therapy Needs - (11/20/23)
     
  44. AASLD: Daily Aspirin Therapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial - (11/20/23)
     
  45. AASLD: THE RISK OF LIVER FIBROSIS IS GREATEST IN AREAS OF HIGHER SOCIOECONOMIC DEPRIVATION: A RISK-FACTOR BASED POPULATION SCREENING STUDY 33% vs 10% - (11/19/23)
     
  46. AASLD: IDENTIFICATION OF THE ENVIRONMENTAL POLLUTANTS AND METABOLIC PATHWAYS ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE SEVERITY - (11/19/23)
     
  47. AASLD: AN AGE-STATIN INTERPLAY IN PREVENTING THE DEVELOPMENT OF CIRRHOSIS IN A 10-YEAR COHORT OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) - (11/19/23)
     
  48. AASLD: Artificial Intelligence to Measure Fibrosis Change on Liver Biopsy - (11/15/23)
     
  49. AASLD: Artificial Intelligence-based Measurement of NASH Histology (AIM-NASH) recapitulates primary results from Phase 3 study of resmetirom for treatment of NASH/MASH with liver fibrosis - (11/15/23)
     
  50. AASLD: RELATIONSHIP OF NON-INVASIVE MEASURES WITH HISTOLOGICAL RESPONSE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL - (11/15/23)
     
  51. AASLD: RESMETIROM IMPROVES THE ATHEROGENIC LIPID/LIPOPROTEIN PROFILE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL - (11/14/23)
     
  52. AASLD: Resmetirom treatment helps restore thyroid hormone levels in patients with nonalcoholic steatohepatitis: 52-week data from the Phase 3 MAESTRO-NASH trial - (11/14/23)
     
  53. AASLD: Economic and social burden of MASLD [fatty liver] in the United States - (11/14/23)
     
  54. AASLD: Increased Risk for NAFLD, MASLD to 34% - (11/08/23)
     
  55. IDWeek: Tesamorelin reduces visceral tissue and liver fat in INSTI-treated persons with HIV - Mark Mascolini (10/16/23)
     
  56. Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis - (10/03/23)
     
  57. IAS: Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis - (08/14/23)
     
  58. IAS: Association between non-alcohol steatohepatitis with significant activity and fibrosis and neurocognitive impairment in people with HIV - (08/02/23)
     
  59. New Name for NAFLD - MASLD - (07/18/23)
     
  60. EASL: Non-alcoholic fatty liver disease awareness, misperception, and their association with healthcare access in Korean general population: a nationally representative survey - (07/11/23)
     
  61. EASL: Non-alcoholic steatohepatitis disease progression in participants from the United States TARGET-NASH real world longitudinal observational study - (07/10/23)
     
  62. EASL: SAFE Score Rates Liver Disease Risk Well in US General Population - Who is SAFE from chronic liver disease? A population-based approach for early detection in the US. - Mark Mascolini (07/05/23)
     
  63. EASL: Significant dose-dependent reduction in liver stiffness using transient elastography in a phase 3 randomized placebo-controlled trial of obeticholic acid over 48 months in patients with pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis - (07/05/23)
     
  64. EASL: A global research priority agenda to advance public health responses to fatty liver disease - (07/05/23)
     
  65. EASL: Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial - (07/05/23)
     
  66. EASL: Use of antidiabetic and lipid-lowering medications associated with lower scores of liver fibrosis biomarkers in non-alcoholic steatohepatitis (NASH) patients - (07/05/23)
     
  67. EASL: Resmetirom Improves the Lipid/Lipoprotein Profile in Patients With Nonalcoholic Fatty Liver Disease - (07/03/23)
     
  68. EASL: Resmetirom Helps Regulate Thyroid Hormone Levels Within the Liver in Patients With Nonalcoholic Fatty Liver Disease - (07/03/23)
     
  69. EASL: Resmetirom Helps Regulate Thyroid Hormone Levels Within the Liver in Patients With Nonalcoholic Fatty Liver Disease - (07/03/23)
     
  70. EASL: Imaging and Biomarker Thresholds to Accurately Diagnose NASH Cirrhosis in a 180-patient Biopsy-confirmed Cohort - (07/03/23)
     
  71. EASL: Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH: a Phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo - (07/03/23)
     
  72. EASL: Liver-Derived Progenitor Cells Ease Fibrosis, Inflammation in NASH - Mark Mascolini (06/30/23)
     
  73. EASL: Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN) - (06/30/23)
     
  74. EASL: MAFLD is better than ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct antiviral agents - (06/30/23)
     
  75. EASL: Timed Calorie Cuts Beat Standard Dieting for Fibrosis, Metabolic Measures With NAFLD - Mark Mascolini (06/28/23)
     
  76. EASL: Early Trials of siRNA ALN-HSD for NASH Show Safety, Drop in Target mRNA - Mark Mascolini (06/28/23)
     
  77. EASL: Resmetirom Resolves NASH and Lessens Fibrosis in 52-Week Placebo Trial - Mark Mascolini (06/28/23)
     
  78. EASL: FASN Inhibitor Denifanstat Improves NASH Markers in 26-Week Analysis - Mark Mascolini (06/28/23)
     
  79. EASL: Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial - (06/28/23)
     
  80. EASL: Pemvidutide Cuts NAFLD Liver Fat and Weight Through 24 Weeks - Mark Mascolini (06/28/23)
     
  81. EASL: Efinopegdutide Cuts Liver Fat More Than Semaglutide in 24 Weeks - Mark Mascolini (06/28/23)
     
  82. EASL: Resmetirom Resolves NASH and Lessens Fibrosis in 52-Week Placebo Trial - Mark Mascolini (06/28/23)
     
  83. EASL: Intrahepatic Characterization of Virological and Immunological Markers in Two Distinct Populations of Chronic Hepatitis B: Baseline Assessment of Core Liver and Fine Needle Aspiration Biopsies From the Investigational INSIGHT Study - (06/28/23)
     
  84. EASL: A Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide in individuals with nonalcoholic fatty liver disease - (06/28/23)
     
  85. EASL: NAFLD Efinopegutide Phase 2a/ Fatty Liver New Drugs-Public Health Research/Survey - (06/28/23)
     
  86. EASL: AI To Measure Fibrosis in MAESTRO-NASH Study with Resmetirom - (06/28/23)
     
  87. CROI: Summary from CROI 2023 for HIV and liver disease What is new in viral hepatitis coinfection? Is fatty liver disease a growing concern? New insights from CROI 2023. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/16/23)
     
  88. CROI: Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study - (03/16/23)
     
  89. CROI: SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (03/16/23)
     
  90. CROI: Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany (03/21/23)
     
  91. EASL: Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis - (06/26/23)
     
  92. EASL: Smoking and obesity promote systemic inflammation in patients with compensated and decompensated cirrhosis - (06/25/23)
     
  93. EASL: Effects of Nutritional Therapy on Sarcopenia in Patients with Liver Cirrhosis - A Randomized Controlled Trial - (06/25/23)
     
  94. Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US (SARONAPLUS) - (06/16/23)
     
  95. Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH - (06/01/23)
     
  96. Evolving NAFLD Models of Care & Future Perspectives - Prof. Jeffrey Lazarus (Global Hepatitis Summit 2023 April 28 Paris) - (05/08/23)
     
  97. The number of new cases and deaths from liver cancer could rise by >55% by 2040. Global burden of primary liver cancer in 2020 and predictions to 2040 - (04/09/23)
     
  98. INTERCEPT ANNOUNCES FDA ADVISORY COMMITTEE MEETING DATE FOR OBETICHOLIC ACID AS A TREATMENT FOR PRE-CIRRHOTIC LIVER FIBROSIS DUE TO NASH PRESS RELEASE - (03/14/23)
     
  99. CROI: VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL - (03/01/23)
     
  100. CROI: PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV - (02/21/23)
     
  101. CROI: CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD - (02/21/23)
     
  102. CROI: SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (02/21/23)
     
  103. CROI: NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV - (02/21/23)
     
  104. CROI: LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE - (02/21/23)
     
  105. New AASLD Fatty Liver Guidelines - (02/06/23)
     
  106. OCA Obeticholic Acid Update at NASH-TAG Jan 5 2023 - (01/16/23)
     
  107. Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023 - press release    - (01/16/23)
     
  108. Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH - press release    - (01/16/23)
     
  109. New NASH Resmetirom Phase 3 Data at NASH-TAG Conference Jan 5    - (01/16/23)
     
  110.  Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis    - (01/13/23)
     
  111.  Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications   - (01/02/23)
     
  112. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review   - (01/02/23)
     
  113. Lean Fatty Liver Disease, NAFLD & Visceral Adiposity   - (12/29/22)
     
  114. Lean Fatty Liver Disease & Visceral Afiposity - (12/29/22)
     
  115. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis - (12/12/22)
     
  116. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection - (12/01/22)
     
  117. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV - (12/01/22)
     
  118. Subclinical cardiac disease in children with perinatally acquired HIV is associated with inflammation - Editorial Comments - (12/01/22)
     
  119. Higher epicardial fat in older adults living with HIV with viral suppression and relationship with liver steatosis, coronary calcium and cardiometabolic risks - (12/01/22)
     
  120. AASLD: Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results - (11/29/22)
     
  121. AASLD: Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022 - (11/28/22)
     
  122. AASLD: Topline Results From a New Analysis of the REGENERATE Trial of Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis - (11/28/22)
     
  123. AASLD: Clinical and Histologic Factors Associated with Discordance Between Steatosis grade Derived From Histology Versus MRI-PDFF in Patients with NAFLD - (11/22/22)
     
  124. AASLD: Increase in Liver Stiffness Measurement (Fibroscan) by Vibration-Controlled Transient Elastography is Associated with Poor Clinical Outcomes in NAFLD - (11/22/22)
     
  125. AASLD: MEFIB-Index and MAST-score in assessment of hepatic decompensation in NAFLD- an individual -patient data meta-analysis - (11/22/22)
     
  126. AASLD: 2 New NASH Drugs in Development - (11/22/22)
     
  127. AASLD: Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) - press release - (11/22/22)
     
  128. AASLD: PXL065 (DEUTERIUM-STABILIZED R-ENANTIOMER OF PIOGLITAZONE) REDUCES LIVER FAT CONTENT AND IMPROVES LIVER HISTOLOGY WITHOUT PPARy -MEDIATED SIDE EFFECTS IN PATIENTS WITH NASH: ANALYSIS OF A 36 WEEK PLACEBO-CONTROLLED PHASE 2 TRIAL (DESTINY1) - (11/22/22)
     
  129. AASLD: The bispecific anti-FGFR1/KLB agonist antibody bFKB1 attenuates non-alcoholic steatohepatitis and atherosclerosis in Ldlr-/-.Leiden mice - (11/22/22)
     
  130. AASLD: Updated Practice Guidance Fatty Liver, NAFLD State of The Art New Practice Guidelines for NAFLD - (11/21/22)
     
  131. AASLD: HIGHER MORTALITY AMONG LEAN VERSUS NON- LEAN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE DESPITE LOWER INCIDENCE OF CIRRHOSIS AND CARDIOVASCULAR DISEASE - (11/21/22)
     
  132. AASLD: PREVALENCE OF NAFLD, ADVANCED FIBROSIS, CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN PROSPECTIVELY ASSESSED PATIENTS WITH TYPE 2 DIABETES: A PROSPECTIVE STUDY - (11/21/22)
     
  133. AASLD: FIBROSIS PROGRESSION RATE AMONG DIABETIC VERSUS NON- DIABETIC PATIENTS WITH BIOPSY- PROVEN NONALCOHOLIC FATTY LIVER DISEASE: A MULTICENTER PROSPECTIVE STUDY - (11/21/22)
     
  134. AASLD: Socioeconomic Determinants of Health in Metabolic Dysfunction-associated Fatty Liver Disease - (11/14/22)
     
  135. AASLD: Pediatric Non-Alcoholic Fatty Liver Disease: low resource neighborhoods may increase risk - (11/14/22)
     
  136. AASLD: Combination Therapy With Cilofexor and Firsocostat Improves Plasma Fibrosis Biomarkers in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (11/14/22)
     
  137. AASLD: PEDIATRIC NON- ALCOHOLIC FATTY LIVER DISEASE: RESIDING IN LOW RESOURCE NEIGHBORHOODS MAY INCREASE RISK - (11/14/22)
     
  138. AASLD: Liver-Related Mortality Soared in US After COVID-19 Arrived - Mark Mascolini (11/10/22)
     
  139. AASLD: CHANGES IN MORTALITY DUE TO CHRONIC LIVER DISEASES (CLD) DURING THE COVID- 19 PANDEMIC: DATA FROM THE UNITED STATES' NATIONAL VITAL STATISTICS SYSTEM - (11/10/22)
     
  140. AASLD: NAFLD Is Independent Kidney Disease Risk Factor in People With Cirrhosis - Mark Mascolini (11/10/22)
     
  141. AASLD: Over 90% at Risk for Fibrotic NASH Don't Need Liver Specialist - Mark Mascolini (11/10/22)
     
  142. AASLD: Higher Fibrosis Progression Rate in NAFLD Group With vs Without Diabetes - Mark Mascolini (11/10/22)
     
  143. AASLD: Utility of FIB-4, MRE, MRI-PDFF, & FibroScan to Identify Patients With At-risk F2-F3 NASH Based on Screening Data From a 2000 Patient Biopsy-Confirmed Cohort of Resmetirom Phase 3 Clinical Trial (MAESTRO-NASH) - (11/08/22)
     
  144. AASLD: A 52-Week Phase 3 Clinical Trial of Resmetirom in 180 Patients With Well-Compensated NASH Cirrhosis - (11/08/22)
     
  145. ID Week: Screening for Hepatitis C as Part of an Opioid Stewardship Initiative: Identifying Infected Patients and Analyzing Linkage to Care - (10/26/22)
     
  146. (Fibroscan) Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis [with NASH] - (09/27/22)
     
  147. EFX Expanded Access Policy - (09/20/22)
     
  148. In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks - (09/20/22)
     
  149. Lean NAFLD can range from 7% to 10% in the United States - (08/18/22)
     
  150. Non-Invasive Testing - Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis - (08/18/22)
     
  151. IAC: Incidence and disease severity of non-alcoholic fatty liver disease among people living with HIV in Thailand - (08/09/22)
     
  152. ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD? Editorial - (07/25/22)
     
  153. EASL: NAFLD Pipeline - by Rohit Loomba MD - (07/21/22)
     
  154. EASL: The MRI and AST (MAST) Score Is Correlated With Noninvasive and Histologic Markers of Fibrosis in Patients With Advanced Fibrosis Due to NASH - (07/13/22)
     
  155. EASL: Inhibition of Tumor Progression Locus 2 Halts the Progression of Liver Fibrosis in a Stringent Long-term Choline-Deficient High-Fat Diet Rat Model - (07/13/22)
     
  156. EASL: Low carbohydrate high fat diet versus low-fat diet on NAS and HbA1c in people with type 2 diabetes - a randomised controlled trial Results from the REDUCTION trial - (07/08/22)
     
  157. EASL: Utility of FIB-4 Thresholds to Identify Patients With At-risk F2-F3 NASH Based on Screening Data From a 2000 Patient Biopsy-Confirmed Cohort of Resmetirom Phase 3 Clinical Trial (MAESTRO-NASH) - (07/06/22)
     
  158. EASL: Biomarkers, Imaging, & Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor Beta Agonist, for 52 Weeks - (07/06/22)
     
  159. EASL: Retrospective AI-based Measurement of NASH Histology (AIM-NASH) Analysis of Biopsies From Phase 2 Study of Resmetirom Confirms Significant Treatment-induced Changes in Histologic Features of Nonalcoholic Steatohepatitis - (07/06/22)
     
  160. EASL: A higher Fibrosis-4 (FIB-4) score is associated with higher healthcare costs and hospitalizations in patients with nonalcoholic steatohepatitis (NASH) - (07/06/22)
     
  161. Can treatment, without prevention, eliminate hepatitis C among men who have sex with men? Commentary - (07/02/22)
     
  162. EASL: More Alcohol Public Health Policies Tied to Fewer Alcohol, Cirrhosis, CVD Deaths, HCC - Mark Mascolini - (07/01/22)
     
  163. EASL: Waist-to-Hip Ratio Predicts Liver Disease Better Than Body Mass Index - Mark Mascolini - (07/01/22)
     
  164. EASL: Lifestyle factors and population attributable risk of hepatocellular carcinoma in lean vs non-lean populations - More Coffee Tied to Lower Liver Cancer Risk in US Group - Mark Mascolini - (07/01/22)
     
  165. EASL: Validation of the new 2021 EASL algorithm for the non-invasive diagnosis of advanced liver fibrosis in non-alcoholic fatty liver disease EASL Algorithm Accurate for Advanced Fibrosis in NAFLD - Mark Mascolini (07/01/22)
     
  166. EASL: Leronlimab, mAb to CCR5, Trims Liver Fat in 14-Week Trial of NASH Patients - Mark Mascolini - (07/01/22)
     
  167. EASL: FibroScan Score Predicts Liver Outcomes in HIV+ With NAFLD Risk - Mark Mascolini - (07/01/22)
     
  168. EASL: Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial - (07/01/22)
     
  169. EASL: Health-related quality of life is impaired in people living with HIV and hepatic steatosis - (06/30/22)
     
  170. EASL: Impact of Resmetirom-Mediated Reductions in Liver Volume & Steatosis Compared With Placebo on the Quantification of Fibrosis Using Second Harmonic Generation in a Serial Liver Biopsy Study - (06/30/22)
     
  171. EASL: Primary Data Analyses of MAESTRO-NAFLD-1:a 52-week Double-blind, Placebo-controlled Phase 3 Clinical Trial of Resmetirom in Patients With NAFLD - (06/27/22)
     
  172. EASL: Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL's International Liver Congress™ - (06/27/22)
     
  173. EASL: The Global Burden of Liver Cancer (LC) and Chronic Liver Diseases (CLD) is Driven by Nonalcoholic Steatohepatitis (NASH) and Alcohol Liver Disease (ALD) - (06/27/22)
     
  174. EASL: Fibroscan-AST (FAST) score predicts liver-related outcomes in 1683 HIV-infected patients at risk for NAFLD - (06/24/22)
     
  175. A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) - (06/21/22)
     
  176. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus - NASH pipeline, phase 3 - (06/06/22)
     
  177. LIVER VOLUME REDUCTION IN RESMETIROM TREATED NON-CIRRHOTIC AND CIRRHOTIC NASH PATIENTS - (06/03/22)
     
  178. Improving NASH [Resmetirom] with a little help from thyromimetics -Comment - (06/03/22)
     
  179. BIOMARKERS, IMAGING AND SAFETY IN RESMETIROM 52-WEEK NON-CIRRHOTIC NASH PHASE 3 CLINICAL TRIAL, COMPLETED OPEN-LABEL ARM OF MAESTRO-NAFLD-1 - (06/03/22)
     
  180. MRI-PDFF, MRE, Fibroscan for Fibrosis, Fatty Liver - (06/03/22)
     
  181. UTILIZATION OF THE MAST (MRI-PDFF-MRE-AST) SCORE TO PREDICT NASH ON LIVER BIOPSY IN MAESTRO-NASH AND ASSESS RESPONSE TO RESMETIROM IN MAESTRO-NAFLD-1 - (06/03/22)
     
  182. PLWH & Fatty Liver Disease, NAFLD. Lifestyle Interventions - (06/02/22)
     
  183. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH - (06/02/22)
     
  184. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - (06/02/22)
     
  185. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial - (06/02/22)
     
  186. NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH - Will Not Pursue Phase 3 - (06/02/22)
     
  187. Aramchol in NASH Phase 3; Expanded Access - (06/01/22)
     
  188. Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health - Expanded Access Program - (06/01/22)
     
  189. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome - (05/23/22)
     
  190. Prevalence of nonalcoholic fatty liver disease using noninvasive techniques among children, adolescents, and youths living with HIV - (05/23/22)
     
  191. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population - (05/23/22)
     
  192. Fatty Liver NAFLD in HIV: Higher Prevalence, Metabolics & ALT/AST Predict - (05/11/22)
     
  193. NAFLD Is Increasingly Affecting Patients With HIV - (05/11/22)
     
  194. HIV is associated with elevated FibroScan-AST (FAST) score - (05/03/22)
     
  195. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study - patients with MetS had the highest prevalence of NAFLD (71%) - (04/20/22)
     
  196. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis - (04/20/22)
     
  197. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study - patients with MetS had the highest prevalence of NAFLD (71%) - (04/20/22)
     
  198. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association - (04/20/22)
     
  199. Senolytics for Poets - (03/24/22)
     
  200. CROI: NON-OBESE NAFLD IS ASSOCIATED WITH HIGHER SCD14 CONCENTRATIONS IN ADULTS WITH HIV - (03/11/22)
     
  201. CROI: 11% - HIGH INCIDENCE RATE OF CT-MEASURED NAFLD IN MACS MEN WITH AND WITHOUT HIV INFECTION - (03/11/22)
     
  202. CROI: DETERMINANTS OF LIVER STEATOSIS IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY - ALT matters - (03/11/22)
     
  203. CROI: IMPACT OF NASH ON THE SURVIVAL OF PEOPLE LIVING WITH HIV - (03/11/22)
     
  204. CROI: PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE VERTICALLY HIV-INFECTED YOUTHS - (03/11/22)
     
  205. CROI: Effect of Tenofovir on T-cell Maturational Subsets in Long Term Aviraemic HIV Adults - (03/11/22)
     
  206. CROI: NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS - (03/11/22)
     
  207. CROI: The role of HIV/HBV/HCV triple infection in end stage liver disease (ESLD) and all cause mortality in Europe (02/23/22)
     
  208. CROI: From NAFLD to MAFLD: implications of change in terminology in PWH - (02/22/22)
     
  209. CROI: NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS - (02/22/22)
     
  210. Fatty Liver (NAFLD) in HIV+ Young, Children, Adolescents - (02/08/22)
     
  211. NASH Pipeline - (02/05/22)
     
  212. Fatty Liver in HIV: higher prevalence, progresses faster, ALT/AST Predict - (02/02/22)
     
  213. NASH & NAFLD - Exercise & 7-10% Weight Loss Recommended - Kathleen Corey, MD. NYU Webcast - Nov 19 2021 - (01/12/22)
     
  214. AASLD: CONCURRENT FATTY LIVER IS ASSOCIATED WITH HIGHER RISK OF HEPATOCELLULAR CARCINOMA AND MORTALITY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS (12/03/21)
     
  215. AASLD: Liver Stiffness-Based Agile Scores Predict Disease Progression in Patients With Advanced Fibrosis Due to NASH (11/30/21)
     
  216. AASLD: Combination Treatments Including CILO and/or FIR in Addition to SEMA Lead to Greater Improvements and Normalization of Cell Death Marker CK18 M30 in Patients With NASH (11/30/21)
     
  217. AASLD: Impact of Modest Weight Reduction on Serum Markers, Liver Histology, and Disease Progression in Patients with Advanced Fibrosis due to NASH (11/30/21)
     
  218. AASLD: FXR Agonism Elevates Circulating Levels of the Pruritogenic Cytokine IL-31 (11/30/21)
     
  219. AASLD: Pharmacokinetics of Firsocostat, an Acetyl-CoA Carboxylase (ACC) Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist, in Participants with Severe Renal Impairment (11/30/21)
     
  220. AASLD: Combination of an Acetyl-CoA Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in a 3D Human Liver Microtissue Model of Nonalcoholic Steatohepatitis (11/30/21)
     
  221. AASLD: MILD NAFLD IS COMMON IN SEVERELY OBESE ADOLESCENTS AND IMPROVES SIGNIFICANTLY FOLLOWING BARIATRIC SURGERY (11/30/21)
     
  222. AASLD: Impact of Modest Weight Reduction on Serum Markers, Liver Histology, and Disease Progression in Patients with Advanced Fibrosis due to NASH (11/30/21)
     
  223. Arrowhead Announces JNJ-75220795 in Development for NASH - (11/23/21)
     
  224. Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD - (11/23/21)
     
  225. AASLD: Safety and Preliminary Efficacy of the Farnesoid X Receptor Agonist Cilofexor in a 96-week Open-label Extension of a Phase 2 Study of PSC - (11/20/21)
     
  226. AASLD: LIVER-DISTRIBUTED FXR AGONIST TERN-101 DEMONSTRATES FAVORABLE SAFETY AND EFFICACY PROFILE IN NASH PHASE 2a LIFT STUDY - (11/20/21)
     
  227. AASLD: Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 demonstrates robust clinical efficacy and safety in a global Phase 2 randomized placebo-controlled NASH trial conducted in the US and China - (11/20/21)
     
  228. AASLD: FASN Inhibitor TVB-2640 Cuts Liver Fat 28% in US/China NASH Trial - Mark Mascolini (11/20/21)
     
  229. AASLD: HTD1801 Lowers Liver Fat Content With Presumed NASH and Diabetes - Mark Mascolini (11/19/21)
     
  230. AASLD: US Medicare Patients With NAFLD Get Less HCC Surveillance and Curative Therapy - Mark Mascolini (11/16/21)
     
  231. AASLD: INSTIs and DAAs Boost Liver Transplant Survival in HIV+ and HIV+/HCV+ in US - Mark Mascolini (11/16/21)
     
  232. AASLD: Exercise for 20 Weeks Tied to Lower Clotting Risk in Randomized NASH Trial - Mark Mascolini (11/15/21)
     
  233. AASLD: More Steatohepatitis Resolution With Low-Cal Mediterranean Diet Than With Low-Fat Diet - Mark Mascolini (11/15/21)
     
  234. AASLD: Incidence and clinical characteristics of hepatocellular carcinoma associated with nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis - Mark Mascolini (11/15/21)
     
  235. AASLD: Burden of Illness and Economic Impact of Nonalcoholic Steatohepatitis (NASH) in the United States According to the Presence of Obesity - (11/15/21)
     
  236. AASLD: Simple Tool Tells Primary Care Docs When to Refer People With NAFLD - Mark Mascolini - (11/15/21)
     
  237. AASLD: HIV is independently associated with elevated FibroScan-AST (FAST) score, a non-invasive measurement of non-alcoholic steatohepatitis with significant activity and fibrosis - Mark Mascolini - (11/15/21)
     
  238. AASLD: Non-alcoholic Steatohepatitis is the Most Common Indication for Liver Transplantation among the Elderly: Data from the U.S. Scientific Registry of Transplant Recipients - (11/13/21)
     
  239. AASLD: Non-Overweight Patients with Nonalcoholic Fatty Liver Disease, Diabetes Fare Worse Than Overweight Patients Before and After Liver Transplant - (11/12/21)
     
  240. AASLD: The Need for Liver Transplants Is Skyrocketing Among Older Americans - (11/12/21)
     
  241. EACS: Liver disease in people living with HIV (PLWHIV) after the microelimination of HCV infection: non-viral hepatitis & NAFLD - (11/02/21)
     
  242. EACS: Maraviroc or Metformin Does Not Lower Liver Fat in People With HIV and NAFLD - Mark Mascolini (11/01/21)
     
  243. EACS: Hepatic steatosis associated with integrase strand transfer inhibitors - does the substance matter? - (11/01/21)
     
  244. Nonalcoholic Steatohepatitis - Opportunities and Challenges- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH - (10/25/21)
     
  245. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  246. Fatty Liver in HIV - (07/18/17)
     
  247. Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease A Randomized Clinical Trial - NASH, hypertension, lipids, liver enzymes, weight loss - (10/20/17)
     
  248. Fatty Liver in HIV+ at IAS - (08/05/17)
     
  249. Fatty Liver / NASH at EASL - (07/03/17)
     
  250. IDWeek: Fatty Liver Disease in HIV: Predictors and Response to Statin Therapy - (10/11/17)
     
  251. IDWeek: Faster Fatty Liver Progression With Statin Than Placebo in SATURN HIV Trial - Mark Mascolini (10/11/17)
     
  252. EASL: Serum Cholesterol Changes Associated with NGM282 Treatment in Obese Insulin Resistant Cynomolgus Monkeys and NASH Patients are Reversed with Lipid Lowering Agents - (04/24/17)
     
  253. EASL: NGM282, a Novel Variant of FGF19, Significantly Reduces Hepatic Steatosis and Key Biomarkers of NASH: Results of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo Controlled Trial in Biopsy-Confirmed NASH Patients - (04/24/17)
     
  254. EASL: Efficacy and Safety of Simtuzumab for the Treatment of NASH with Bridging Fibrosis or Cirrhosis: Results of Two Phase 2b, Dose-Ranging, Randomized, Placebo-Controlled Trials - (05/23/17)
     
  255. Fatty Liver, NAFLD, NASH Definitions - (06/29/17)
     
    ------------
     
  256. Fatty Liver Disease & Non-Viral Hepatitis in PLWH - (08/15/21)
     
  257. Comparison of ADAPT, FIB4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR Screening Population - (08/30/21)
     
  258. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States - (08/15/21)
     
  259. Associations of Hepatosteatosis With Cardiovascular Disease in HIV-Positive and HIV-Negative Patients: The Liverpool HIV-Heart Project - (08/15/21)
     
  260. EASL: Combinations of an Acetyl Coenzyme-A Carboxylase Inhibitor, FXR Agonist, and GLP-1R Agonist Inhibit Fibrosis Progression in the Rat Choline-Deficient, L-Amino-Acid-Defined, High-Fat Diet Model of Advanced Fibrosis - (07/14/21)
     
  261. EASL: The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry - (07/12/21)
     
  262. EASL: Liver Stiffness by Vibration-Controlled Transient Elastography Predicts Disease Progression in Patients With Advanced Fibrosis Due to NASH - (07/12/21)
     
  263. EASL: Trimming FAST Score 0.2 Points Improves NASH Over 72 Weeks - Mark Mascolini (07/09/21)
     
  264. EASL: Lower Response to Pfizer COVID Vaccine in Older People With Advanced Fibrosis - Mark Mascolini (07/09/21)
     
  265. EASL: New FibroScan Score Improves Advanced Fibrosis Detection in NAFLD - Mark Mascolini (07/09/21)
     
  266. EASL: NASH Fibrosis Rate 2% in General Population of Spain-1.3% With Treatable Fibrosis - Mark Mascolini (07/05/21)
     
  267. EASL: Fibrosis, Liver Markers Improve in F4 NASH With Once-Weekly Efruxifermin - Mark Mascolini (07/05/21)
     
  268. EASL: Cilofexor and Firsocostat Treatment Is Associated With Widespread Changes in the Hepatic Transcriptome in NASH Patients With Advanced Fibrosis - (07/05/21)
     
  269. EASL: Higher Risk of Liver Events, Nonliver Cancer, Death With Lean vs Nonlean NAFLD - Mark Mascolini (07/05/21)
     
  270. EASL: About 2-Fold Higher Risk of MI, HCC, CKD When NASH Patients Have Cirrhosis - Mark Mascolini (07/05/21)
     
  271. EASL: Higher Risk of Liver Events, Nonliver Cancer, Death With Lean vs Nonlean NAFLD - Mark Mascolini (07/05/21)
     
  272. EASL: About 2-Fold Higher Risk of MI, HCC, CKD When NASH Patients Have Cirrhosis - Mark Mascolini (07/05/21)
     
  273. EASL: Prevalence of non-alcoholic fatty liver in The Netherlands: the Netherlands Epidemiology of Obesity study - (06/29/21)
     
  274. EASL: NAFLD Doubles Risk of CVD and Cuts up to 6 Years off Life Expectancy - Mark Mascolini (06/26/21)
     
  275. EASL: Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review - (06/26/21)
     
  276. EASL: Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review Together, HBV and HCV Less Prevalent in Cirrhosis Than in HCC Cases Worldwide - Mark Mascolini (06/26/21)
     
  277. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial - (06/24/21)
     
  278. EASL: Chronic liver disease and risk of mortality after COVID-19: a national, retrospective, cohort study for 2020 - Mark Mascolini (06/24/21)
     
  279. EASL: ASSOCIATION OF MAFLD WITH MORTALITY IN PATIENTS WITH COVID-19 IN MEXICO - (06/23/21)
     
  280. EASL: Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after Direct-acting Hepatitis C therapeutics corresponds to a lower incidence rate of hepatocellular carcinoma below the cost-effective threshold for surveillance - (06/23/21)
     
  281. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard - (06/15/21)
     
  282. Belly Fat Predicts Fibrosis - Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease - (06/15/21)
     
  283. NAFLD Management - Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial - (06/9/21)
     
  284. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study - (05/3/21)
     
  285. CROI: Summary from virtual CROI 2021 for HIV and liver disease HIV and the liver: hot topics - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (04/10/21)
     
  286. Non-Viral Liver Disease in HIV+ - Increased Prevalence of Liver Fibrosis in PLWH Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls - (03/02/21)
     
  287. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study - (02/10/21)
     
  288. AASLD EXPERT PANEL CONSENSUS STATEMENT: VACCINES TO PREVENT COVID-19 INFECTION IN PATIENTS WITH LIVER DISEASE - (02/08/21)
     
  289. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients - (02/08/21)
     
  290. AASLD: NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ASSOCIATES WITH HIGHER RISK OF DEVELOPING SYMPTOMATIC COVID19 INFECTION - INITIAL UK BIOBANK OBSERVATIONS - (02/01/21)
     
  291. Study Suggests Fatty Liver and Cirrhosis Doubles Mortality Risk in COVID-19 - (02/01/21)
     
  292. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study - (02/01/21)
     
  293. Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis - (02/01/21)
     
  294. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States - (02/01/21)
     
  295. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study - (01/30/21)
     
  296. The prevalence of NAFLD in Africa was estimated to be about 13% - The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD - (01/20/21)
     
  297. Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration - (01/14/21)
     
  298. AASLD: Efficacy and safety of subcutaneous semaglutide once-daily versus placebo in patients with nonalcoholic steatohepatitis
    Semaglutide Resolves NASH in Big Placebo-Controlled Trial     - (01/07/21)
     
  299. AASLD: HIGH PREVALENCE OF FATTY LIVER DISEASE [FLD] AND ADVANCED FIBROSIS IN AN URBAN MULTIETHNIC US COHORT OF PERSONS WITH HIV - (12/21/20)
     
  300. AASLD: PREVALENCE AND RISK FACTORS OF HEPATIC STEATOSIS AND FIBROSIS IN AMERICAN ADULTS: A POPULATION-BASED STUDY - (12/21/20)
     
  301. AASLD: GLOBAL PREVALENCE OF HEPATITIS C VIRUS IN WOMEN OF CHILDBEARING AGE IN 2019: A MODELING STUDY - (12/21/20)
     
  302. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (12/21/20)
     
  303. AdverseReactComor: Non-alcoholic fatty liver disease (NAFLD) in HIV-monoinfected patients: results from the European ECHAM study - (12/14/20)
     
  304. AASLD: NAFLD AND ALCOHOL-RELATED LIVER DISEASE ARE PRIMARY DRIVERS OF CURRENT AND FUTURE CAUSES OF CIRRHOSIS AMONG WOMEN IN NORTH AMERICA - (12/03/20)
     
  305. AASLD: SEMAGLUTIDE TREATMENT IN SUBJECTS WITH NAFLD: EFFECTS ASSESSED BY MAGNETIC RESONANCE ELASTOGRAPHY AND MAGNETIC RESONANCE IMAGING PROTON DENSITY FAT FRACTION - (12/02/20)
     
  306. AASLD: RESOLVE-IT Phase 3 of Elafibranor in NASH: Final Results of the Week 72 Interim Surrogate Efficacy Analysis - (12/02/20)
     
  307. AASLD: HCC, Decompensation, Alcohol, Tied to Death in Liver Patients With COVID-19 - Mark Mascolini (12/01/20)
     
  308. AASLD: Predictors Of Outcomes Of Covid-19 In Patients With Chronic Liver Disease: US Multi-center Study. - (12/01/20)
     
  309. AASLD: A 52-WEEK MULTI-CENTER DOUBLE-BLIND RANDOMIZED PHASE 2 STUDY OF SELADELPAR, A POTENT AND SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPAR-DELTA) AGONIST, IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) - (12/01/20)
     
  310. AASLD: What Are the Current Treatment Options for our Patients with NAFLD/NASH ? - (12/01/20)
     
  311. AASLD: Patient-Reported Outcomes in Patients with Chronic Hepatitis C: Data from the Global Liver Registry - (12/01/20)
     
  312. AASLD: FIB -4 and FibroScan Can Identify Patients With Nonalcoholic Fatty Liver Disease Who Are at Risk of Liver-Related Events: Results of a Longitudinal Analysis With Comparison With Liver Biopsy - (12/01/20)
     
  313. AASLD: Identification of Undiagnosed NASH: Development and Application of a Real-world Prediction Model - (12/01/20)
     
  314. AASLD: ECONOMIC BURDEN OF NASH-ASSOCIATED CIRRHOSIS: US PAYOR'S PERSPECTIVE - (12/01/20)
     
  315. AASLD: Noninvasive Assessments to Identify Patients With Advanced Fibrosis Due to NASH: Screened Population From the REGENERATE Trial - (12/01/20)
     
  316. AASLD: Evaluation of Obeticholic Acid Efficacy in Patients With NASH Who Were Monitored Using Noninvasive Tests: A Post Hoc Analysis of the REGENERATE Trial - (12/01/20)
     
  317. AASLD: Prediction accuracy of the NASHmap algorithm designed to screen for presence of NASH - (12/01/20)
     
  318. AASLD: Prediction accuracy of the NASHmap algorithm designed to screen for presence of NASH - (12/01/20)
     
  319. AASLD: In 20-Year NAFLD Study, Lean Have Higher Death Rate Than Obese - Mark Mascolini (12/01/20)
     
  320. AASLD: Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study - (11/24/20)
     
  321. AASLD: Systematic Review and Meta-analysis of FIB-4 for the Diagnosis of Advanced Fibrosis due to Nonalcoholic Steatohepatitis - (11/24/20)
     
  322. AASLD: Final analysis of a 24-week, randomized, double blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - Mark Mascolini (11/24/20)
     
  323. AASLD: Novel, first-in-class, fatty acid synthase (FASN) inhibitor, TVB-2640 demonstrates clinically significant reduction in liver fat by MRI-PDFF, and ALT in NASH: a phase 2 randomized placebo controlled TRIAL (FASCINATE-1). - Mark Mascolini (11/24/20)
     
  324. AASLD: Safety and Drug-Drug Interaction of Tropifexor in Combination With Licogliflozin in Healthy but Overweight to Obese Subjects in Support of a Ph2b Combination Study ELIVATE - (11/24/20)
     
  325. AASLD: LIK066 (LICOGLIFLOZIN), AN SGLT1/2 INHIBITOR, IMPROVES MARKERS OF HEPATIC AND METABOLIC HEALTH IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: FULL STUDY ANALYSIS OF A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2A STUDY - (11/24/20)
     
  326. AASLD: Cilofexor and Firsocostat in Combination Lead to Greater Reductions in Serum Bile Acids, Which Are Associated With Treatment Response in Patients With Advanced Fibrosis Due to NASH - (11/24/20)
     
  327. AASLD: Combination Treatment With Cilofexor and Firsocostat Normalizes Cell Death Marker Cytokeratin 18 in Patients With Advanced Fibrosis Due to NASH - (11/24/20)
     
  328. AASLD: North America's Largest Meta-Analysis on the Prevalence of NAFLD, NASH, and Advanced Fibrosis (F3-F4) - (11/24/20)
     
  329. AASLD: Validation of a Machine Learning-Based Approach (DELTA Liver Fibrosis Score) for the Assessment of Histologic Response in Patients With Advanced Fibrosis Due to NASH - (11/24/20)
     
  330. AASLD: Clinical characteristics used for machine learning identification of fast progressors among patients with NASH - (11/24/20)
     
  331. AASLD: A phase 2, randomized, double-blind, placebo-controlled dose-finding study of the efficacy and safety of namodenoson (CF102), an A3 adenosine receptor (A3AR) agonist, in treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). - A3AR Agonist Improves NAFLD-Related Variables in Phase 2 Trial - (11/24/20)
     
  332. AASLD: Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study - (11/24/20)
     
  333. AASLD: Survival After Liver Transplant Similar With NASH and Other Causes - Mark Mascolini (11/24/20)
     
  334. AASLD: Obesity Plus High Liver Fat Boost Odds of Hospital Admission With Severe COVID-19 -Mark Mascolini (11/24/20)
     
  335. AASLD: Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - Mark Mascolini - (11/24/20)
     
  336. AASLD: Lipid Management in a 24-Week, Randomized, Double-Blind, Placebo-Controlled Study of Aldafermin (NGM282) - (11/23/20)
     
  337. AASLD: Aldafermin (NGM282) Produces Greater Anti-Fibrotic Response in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (11/23/20)
     
  338. AASLD: Final analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - (11/23/20)
     
  339. AASLD: Testosterone Helps Diet and Exercise Improve Sarcopenia in Men With Cirrhosis - Mark Mascolini (11/23/20)
     
  340. AASLD: Change in lipid markers throughout early adulthood is associated with prevalent NAFLD in mid-life: the coronary artery risk development in young adults (CARDIA) study - Mark Mascolini (11/23/20)
     
  341. AASLD: The microbiome changes induced by bariatric surgery protects against obesity and nonalcoholic fatty liver disease by decreasing gastric inhibitory protein and increasing hepatic NKT cell expression - Mark Mascolini (11/20/20)
     
  342. AASLD: A Random Forest Classifier Based on a 30-Gene Signature Distinguishes Patients With Bridging Fibrosis From Those With Cirrhosis Due to NASH (11/20/20)
     
  343. AASLD: Fc-FGF21 Fusion Protein Cuts Liver Fat, Improves Fibrosis in 4-Arm NASH Trial - Mark Mascolini (11/20/20)
     
  344. AASLD: Low Liver Fat Tied to Higher CHD Risk in Viscerally Obese People - Mark Mascolini (11/20/20)
     
  345. AASLD: Abnormal Liver Tests at COVID Hospitalization Tied to Severe Disease, Death - Mark Mascolini (11/18/20)
     
  346. AASLD: Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis - (11/17/20)
     
  347. AASLD: Sugary Drinks, High Trans Fats Lead Dietary Risks for Death With NAFLD - Mark Mascolini (11/17/20)
     
  348. AASLD: The Lipidomics of HIV-related NAFLD - (11/17/20)
     
  349. AASLD: Treatment with Growth Hormone-Releasing Hormone Analog ReducesVEGFA, TGFβ1, and CSF1: Mechanisms of Tesamorelin Effect in Nonalcoholic Fatty Liver Disease - (11/17/20)
     
  350. AASLD: Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)
     
  351. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis - (11/05/20)
     
  352. Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study - (11/05/20)
     
  353. EASL: EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects - (09/28/20)
     
  354. EASL EDP-297, a novel and potent fxr agonist, exhibit robust anti- fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis - (09/28/20)
     
  355. EASL A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and in rodent models of liver injury and NASH - (09/28/20)
     
  356. EASL Progression of liver stiffness and the development of cirrhosis in histologically characterized patients with nonalcoholic fatty liver disease A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors - (09/25/20)
     
  357. EASL Progression of liver stiffness and the development of cirrhosis in histologically characterized patients with nonalcoholic fatty liver disease - (09/25/20)
     
  358. EASL Optimal Non-Invasive Screening Strategy for Nonalcoholic Fatty Liver Disease in a Prospective Cohort of Patients with Type 2 Diabetes - (09/25/20)
     
  359. EASL Associations Between Serum Bile-Acid Species With Liver Fibrosis and Prognosis in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  360. EASL Machine Learning Models Accurately Interpret Liver Histology and Are Associated With Disease Progression in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  361. EASL Hepatic Transcriptomic Analysis Identifies a Mast Cell Gene Expression Signature That Correlates With Fibrosis Stage and Is Prognostic in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  362. EASL Removal of Fibrosis-Related Genes Identifies a Hepatic Gene Expression Signature That Identifies Canonical Signaling Pathways and Is Correlated With Clinical Outcomes in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  363. EASL Cotadutide Tames Metabolic Markers in Overweight/Obese With Diabetes - Mark Mascolini - (09/17/20)
     
  364. EASL THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT OF NASH IN THE GENERAL POPULATION - (09/15/20)
     
  365. EASL Myosteatosisis strongly associated with NASH in humans and in preclinical NAFLD models - (09/15/20)
     
  366. EASL Machine learning to predict recurrence of early-stage HCC before therapy using baseline MRI - (09/15/20)
     
  367. EASL Glympse Liver Test for Noninvasive Monitoring of Combination Drug Therapy in a Rat Model of Nonalcoholic Steatohepatitis - (09/15/20)
     
  368. The Pharmacokinetics, Pharmacodynamics, and Short-term Safety of Cilofexor, a Nonsteroidal Farnesoid X Receptor Agonist, in Subjects With Hepatic Impairment - (09/15/20)
     
  369. EASL Concentration-QT Analysis of Firsocostat, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor - (09/15/20)
     
  370. EASL Improvements in the ELF Test Are Associated With Widespread Changes in the Hepatic Transcriptome in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (09/15/20)
     
  371. EASL Machine Learning Models Identify Novel Histologic Features Predictive of Clinical Disease Progression in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (09/15/20)
     
  372. EASL Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH) - (09/15/20)
     
  373. EASL Europe's largest meta-analysis on the prevalence of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and advanced fibrosis (F3-F4) - (09/15/20)
     
  374. EASL Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - (09/15/20)
     
  375. EASL Association of FIB4 score with disease progression in real -world populations diagnosed with NAFLD/NASH or at risk of NASH in US Clinical Practice - (09/04/20)
     
  376. EASL Phenome-Wide Association Study of the FIB-4 Index in a Large, Population-Based Study in the United States - (09/04/20)
     
  377. EASL The Safety and Pharmacokinetics of Fenofibrate in Patients With Advanced Fibrosis, Including Those With Nonalcoholic Steatohepatitis - (09/04/20)
     
  378. EASL Combination of an Acetyl CoA Carboxylase Inhibitor With Therapeutics That Promote Fatty-Acid Oxidation Does Not Improve Antifibrotic Efficacy in a Preclinical NASH Model - (09/04/20)
     
  379. EASL Efficacy and Safety of an Acetyl CoA Carboxylase Inhibitor Are Improved in Combination With PPAR Agonists in a Dyslipidemic Rat Model - (09/04/20)
     
  380. EASL A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH) - (09/04/20)
     
  381. EASL Liver disease progression and clinical outcomes in the Hepatic Outcomes and Survival Fatty liver Registry (HOTSURFR) Study - (09/04/20)
     
  382. EASL FXR Agonist EDP-305 Lowers ALT and Liver Fat in NASH - Mark Mascolini (08/31/20)
     
  383. EASL Nidufexor Lowers ALT and Liver Fat at 12 Weeks in NASH Patients - Mark Mascolini (08/31/20)
     
  384. EASL TVB-2640 Lowers Liver Fat, Improves Fibrosis, in Phase 2a NASH Trial - Mark Mascolini (08/31/20)
     
  385. EASL Liver and Heart Disease, Nonsolid Cancers, Lead Causes of Death With NAFLD - Mark Mascolini (08/31/20)
     
  386. EASL Safety and Efficacy of Combination Therapies Including Cilofexor/Firsocostat in Patients With Bridging Fibrosis and Cirrhosis Due to NASH: Results of the Phase 2b ATLAS Trial (08/31/20)
     
  387. EASL CCR2/5 Antagonist Plus FGF21 Analog Quell Liver Fat, Fibrosis in Mice - Mark Mascolini (08/31/20)
     
  388. EASL NASH and Visceral Fat Tied to Adipose IR Independently of BMI - Mark Mascolini (08/31/20)
     
  389. EASL Despite Evidence of Benefit in NASH, GLP1a and SGLT2i Use Low in US - Mark Mascolini (08/31/20)
     
  390. EASL More Comorbidities With NAFLD/NASH Than Hepatitis in Global Survey - Mark Mascolini (08/31/20)
     
  391. EASL Causes of Death in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Data from National Vital Statistics System (NVSS) - (08/31/20)
     
  392. EASL Multidisciplinary NAFLD Approach Yields Strong CVD Risk Gains - Mark Mascolini (08/27/20)
     
  393. EASL Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials - (08/27/20)
     
  394. EASL Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression Vs Men: A Systematic Review and Meta-analysis - (08/27/20)
     
  395. Characteristics of Liver Tests in COVID-19 Patients - (08/25/20)
     
  396. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury - (08/25/20)
     
  397. SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections - (08/25/20)
     
  398. Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH) - (08/10/20)
     
  399. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection - (08/10/20)
     
  400. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis - (08/10/20)
     
  401. IAC 2020 Virtual: Is NAFLD the same disease in HIV infected patients? - (08/10/20)
     
  402. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD - (07/27/20)
     
  403. Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH - press release - (06/29/20)
     
  404. Fatty Liver in HIV: what the HIV Clinician Needs to Know - (06/19/20)
     
  405. Lean NAFLD in HIV+ 14% - Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus - (06/19/20)
     
  406. Barriers to HCV Treatment: Prior Authorization for PWID Must Be Removed, It Delays Cure & Encourages Disease Progression & Death - (06/19/20)
     
  407. Timing of hepatitis C elimination in the United States: Estimating the year each state will achieve the World Health Organization's elimination targets - (06/19/20)
     
  408. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States - PWID can be successfully cured - (06/19/20)
     
  409. HCV Testing for HIV+ - Only 50% Are Tested - (06/19/20)
     
  410. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes - (06/12/20)
     
  411. DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH - (06/05/20)
     
  412. Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort - (06/01/20)
     
  413. Fatty Liver in HIV - (05/28/20)
     
  414. New HCV Infections Tripled: 4 times Higher than in 2009 - (05/14/20)
     
  415. Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD - (05/12/20)
     
  416. Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/11/20)
     
  417. Non-alcoholic fatty liver disease predicts development of metabolic comorbidities in HIV-infected patients - (05/08/20)
     
  418. Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/08/20)
     
  419. Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/05/20)
     
  420. CROI: Hepatitis, HCV, HBV & Fatty Liver at CROI 2020 - (04/29/20)
     
  421. CROI: NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20)
     
  422. CROI: INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID - 20% ALIVE Cohort (04/02/20)
     
  423. CROI: NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONOINFECTED PATIENT (04/02/20)
     
  424. CROI: BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS (03/23/20)
     
  425. CROI: Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated Nonalcoholic Fatty Liver Disease (03/23/20)
     
  426. CROI: Fibrosis Progression Over 6-Fold Higher in NAFLD With vs Without HIV - Mark Mascolini (03/23/20)
     
  427. CROI: VISCERAL FAT IS A PREDICTOR OF LIVER FIBROSIS AND FIBROSIS PROGRESSION IN PEOPLE LIVING WITH HIV (03/23/20)
     
  428. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD (03/23/20)
     
  429. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/11/20)
     
  430. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/11/20)
     
  431. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease - (02/28/20)
     
  432. Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients - (02/27/20)
     
  433. Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon - (02/04/20)
     
  434. GP perceptions of liver disease; HIV & Fatty Liver/NASH NASH Diagnosis and Management in General Practice - (01/09/20)
     
  435. EACS: Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease (01/13/20)
     
  436. EACS: Hepatic steatosis in HIV+ individuals: which impact has baseline BMI and treatment with integrase inhibitors? (01/13/20)
     
  437. EACS: Evolutive NAFLD predicts frailty in people living with HIV - Mark Mascolini (01/13/20)
     
  438. Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) - (01/09/20)
     
  439. Vitamin E for Fatty Liver in AASLD Guidelines - (01/09/20)
     
  440. Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients - (01/09/20)
     
  441. Obeticholic acid: towards first approval for NASH - Comment - (12/13/19)
     
  442. AASLD: Zydus Announces Positive Results From EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH - (12/13/19)
     
  443. AASLD: Tropifexor (TXR), an FXR Agonist for the Treatment of NASH - Interim Results from First Two Parts of Phase 2b Study FLIGHT-FXR - (12/13/19)
     
  444. AASLD: Effects of Cotadutide (MEDI0382) on Biomarkers of Nonalcoholic Steatohepatitis in Overweight or Obese Subjects with Type 2 Diabetes Mellitus: A 26-Week Analysis of a Randomized Phase 2b Study - (12/13/19)
     
  445. AASLD: SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OBETICHOLIC ACID IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS OR CIRRHOSIS - (12/03/19)
     
  446. AASLD: ASSESSMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA): RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL - (12/03/19)
     
  447. AASLD: Obeticholic Acid Treatment in Patients with Non-alcoholic Steatohepatitis: A Secondary Analysis of the REGENERATE Study Across Fibrosis Stages - (12/03/19)
     
  448. Impact of Prescribed Treatment Duration on Hepatitis C Treatment Adherence: Comparison of 8- and 12-Week Treatment With Glecaprevir/Pibrentasvir - (12/12/19)
     
  449. AASLD: LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study - (12/10/19)
     
  450. AASLD: LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study - (12/09/19)
     
  451. AASLD: Higher Number of Concurrent Metabolic Co-Morbidities Is Associated with Increasingly Higher Risk of Significant Hepatic Fibrosis and Cirrhosis in Nonalcoholic Fatty Liver Disease Patients - (12/09/19)
     
  452. AASLD: MELD-score changes in relation to clinical outcome following DAAs in HCV-infected patients with cirrhosis - (12/09/19)
     
  453. AASLD: Effects of Cotadutide (MEDI0382) on Biomarkers of Nonalcoholic Steatohepatitis in Overweight or Obese Subjects with Type 2 Diabetes Mellitus: A 26-Week Analysis of a Randomized Phase 2b Study - (12/09/19)
     
  454. AASLD: Ultrasound-based Controlled Attenuation Parameter (CAP) to Detect Longitudinal Changes in Liver Fat When Effect Size is Large -Experience From a Phase 2a, Dose-ranging Study Assessing MRI-Proton Density Fat Fraction (PDFF) and CAP In Parallel - (12/05/19)
     
  455. AASLD: PF-05221304 (PF'1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCi), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT-Phase 2a, dose-ranging study - (12/05/19)
     
  456. AASLD: Safety and Efficacy of 10mg (high-dose) bulevirtide (Myrcludex B) in combination with PEG-IFNa or TDF in patients with chronic HBV/HDV co-infection: interim results. - (12/05/19)
     
  457. AASLD: A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study - (12/05/19)
     
  458. AASLD: THE IMPACT OF PRURITUS ON PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA) - (12/05/19)
     
  459. EACS: Non-Alcoholic Fatty Liver Disease is a significant predictor of cardiovascular risk in HIV-mono-infected patients (12/04/19)
     
  460. AASLD: Factors Associated with Mortality in Lean, Overweight and Obese Patients with Non-alcoholic Fatty Liver Disease - (11/25/19)
     
  461. AASLD: Machine Learning Models Accurately Interpret Liver Histology in Patients With Nonalcoholic Steatohepatitis - (11/19/19)
     
  462. AASLD: Innovative Machine Learning Tool Predicts Who Might Have Non-Alcoholic Steatohepatitis - (11/19/19)
     
  463. AASLD: Machine Learning Models Accurately Interpret Liver Histology in Patients With Nonalcoholic Steatohepatitis - (11/19/19)
     
  464. EACS: Fibrosis, Steatosis, and NAFLD Boost Odds of Frailty in HIV Group - Mark Mascolini (11/13/19)
     
  465. Tesamorelin, liver fat, and NAFLD in the setting of HIV - Comment / Tesamorelin Prevented Progression to Liver Fibrosis in NIH Study - (10/25/19)
     
  466. Aging/HIV & Senescence; NASH - (07/08/19)
     
  467. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV.......33% hepatic steatosis >/= grade 1 vs 10% controls - > grade 2 28% vs 5% controls - belly, metabolics - (06/28/19)
     
  468. 20th Intnl Wrkshp Clin Pharm: Alteration of Hepatic OATP Activity Does Not Alter the Pharmacodynamic Effect of GS-0976, a Liver-Targeted ACC Inhibitor, on De Novo Lipogenesis - (05/26/19)
     
  469. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries - (05/24/19)
     
  470. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  471. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis - (05/14/19)
     
  472. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication - (05/13/19)
     
  473. NAFLD in lipodystrophy - (05/10/19)
     
  474. EASL: THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders - (05/09/19)
     
  475. Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) - (05/08/19)
     
  476. EASL: NGM313, a Novel Activator of β-Klotho/FGFR1c: A Single Dose Significantly Reduces Steatosis (Liver Fat by MRI-PDFF), Inflammation (ALT, AST) and FibrogenicActivity (Pro-C3) in NAFLD Subjects - (05/08/19)
     
  477. EASL: Merck (Fatty Liver Disease/NASH) and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022 - (05/08/19)
     
  478. EASL: New Non-Invasive NASH/Fibrosis Biomarkers - A Comparative Study of Fibrosis Treatments using Aptamer-Based Quantitative Proteomics in a Model of Nonalcoholic Steatohepatitis Cirrhosis - (05/08/19)
     
  479. EASL: A Novel Approach to Funding HCV and HBV Treatment for all -Uzbekistan Pilot Project - (05/08/19)
     
  480. EASL: The short and long term impact of scaling up treatment for hepatitis B and C on disease burden - (05/08/19)
     
  481. EASL: A comparison of currently available direct acting antiviral HCV therapy in Canada - On the path to elimination - (05/08/19)
     
  482. EASL: MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/08/19)
     
  483. EASL: MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
     
  484. EASL: Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
     
  485. EASL: A Simple Algorithm Based on Electronic Medical Records to Identify NAFLD with Advanced Fibrosis in Patients with Type 2 Diabetes - (05/07/19)
     
  486. EASL: The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes - (05/07/19)
     
  487. EASL: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (05/07/19)
     
  488. EASL: The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD - (05/07/19)
     
  489. NAFLD in Lean Person EASL - Symposium: Recognising and managing the lean NAFLD patient - (05/01/19)
     
  490. EASL: Food, Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD) - (04/30/19)
     
  491. EASL: LIFESTYLE FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE - (04/30/19)
     
  492. EASL: The socio-economic burden of NASH in Europe and the United States: the GAIN study - (04/26/19)
     
  493. EASL: A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases - (04/23/19)
     
  494. EASL: High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance - (04/23/19)
     
  495. EASL: EASL Wrap-up session: Metabolic and alcohol related liver disease, Fatty Liver/NASH - (04/23/19)
     
  496. EASL: Liver Disease in UK General Population: Fatty & Alcohol Liver Disease; Lack of Awareness: 4% aware; High Rate of Risk Factors: 89% - (04/23/19)
     
  497. FATTY LIVER in HIV+, alcohol, 50% have NAFLD, 27% Liver Fibrosis - The prevalence of liver fibrosis in HIV infected patients with abnormal liver function tests - (04/23/19)
     
  498. EASL: Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis - (04/22/19)
     
  499. EASL: A Combination of the ACC Inhibitor GS-0976 (firsocostat) and the Nonsteroidal FXR Agonist GS-9674 (cilofexor) Improves Hepatic Steatosis, Biochemistry, and Stiffness in Patients With Nonalcoholic Steatohepatitis - (04/22/19)
     
  500. EASL: APPLICATION OF GUIDELINES FOR FATTY LIVER IN TWO PROSPECTIVE COHORTS OF HIV+ PATIENTS: 32% have NAFLD; among those without NAFLD 18% with elevated ALT - (04/22/19)
     
  501. EASL: The Increasing Importance of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Human Immunodeficiency Virus (HIV) - (04/18/19)
     
  502. EASL: Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH - (04/13/19)
     
  503. EASL: HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)
     
  504. The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease - Editorial - (04/10/19)
     
  505. Cirrhosis Causes Cognitive impairment, Poor Patient Outcomes - Despite HCV, SVR in the Presence of NAFLD, Alcoholic Fatty Liver Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis - (04/10/19)
     
  506. Treating Hepatitis C in the Homeless at the Greater Los Angeles Veterans Affairs .....Two thirds of HVs referred for treatment received treatment with 100% [13/13] achieving SVR12. - (04/10/19)
     
  507. Study Confirms Tesamorelin Significantly Reduces Liver Fat in HIV Patients With NAFLD - press announcement - (04/02/19)
     
  508. SHIVER: 1ST INTERNATIONAL WORKSHOP OF THE STEATOHEPATITIS IN HIV EMERGING RESEARCH (SHIVER) NETWORK - (03/01/19)
     
  509. Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) - (02/27/19)
     
  510. Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (01/14/19)
     
  511. Merck Exercises Option for NGM Bio's Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes - (01/08/19)
     
  512. AASLD: Trends in Causes of Mortality in Liver Transplantation Recipients: Comparison Among NASH, ALD, and HCV Cohorts - (01/04/19)
     
  513. AASLD: Health care costs associated with NAFLD - a long-term follow up study - (01/04/19)
     
  514. AASLD: Economic Burden of Progression to Cirrhosis in Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States - (12/14/18)
     
  515. AASLD: Prevalence and Long-term Outcomes of Non-alcoholic Fatty Liver Disease (NAFLD) Among Elderly Individuals from the United States - (12/14/18)
     
  516. AASLD: Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease: The Impact of Alcohol Consumption and Metabolic Syndrome to Mortality - (12/14/18)
     
  517. AASLD: NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis(NASH) Results of a Phase 2 Multi-Center Dose Finding Study - (12/12/18)
     
  518. AASLD: NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study - (12/12/18)
     
  519. AASLD: NGM313, a Novel Once-Monthly Activator of bKlotho-FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Non- Alcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin-Resistant Patients with NAFLD - (12/12/18)
     
  520. AASLD: GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (12/11/18)
     
  521. AASLD: Validation of Fractional Synthesis Rate of Plasma Lumican as a Noninvasive Marker of Fibrogenesis in Patients With Nonalcoholic Steatohepatitis - (12/11/18)
     
  522. AASLD: The Incidence of Malignancies in Nonalcoholic Fatty Liver Disease - (12/11/18)
     
  523. AASLD: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Acetyl-CoA Carboxylase Inhibitor GS-0976, and Phenotypic Probe Substrates and Inhibitors - (12/11/18)
     
  524. AASLD: The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (12/10/18)
     
  525. AASLD: Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis - (11/16/18)
     
  526. AASLD: Rising and Higher Healthcare Resource Utilization (HCRU) and Costs of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Liver Disease of Increasing Severity - Results of a US Real-World Analysis - (11/16/18)
     
  527. AASLD: ASK1 Inhibition Reduces Progression of Liver Cirrhosis and Prevents Tumor Development in the BALB/c.Mdr2-/- Mouse Model of Biliary Fibrosis - (11/15/18)
     
  528. AASLD: Routinely Available Noninvasive Tests Discriminate Advanced Fibrosis Due to NASH in the Phase 3 STELLAR Trials of the ASK1 Inhibitor Selonsertib - (11/15/18)
     
  529. AASLD: GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (11/15/18)
     
  530. AASLD: The Nonsteroidal FXR Agonist GS-9674 Leads to Significant Reductions in Hepatic Steatosis, Serum Bile Acids, and Liver Biochemistry in a Phase 2, Randomized, Placebo-Controlled Trial of Patients With NASH - (11/15/18)
     
  531. AASLD: The Nonsteroidal Farnesoid X Receptor Agonist GS-9674 Improves Liver Biochemistry and Decreases Serum Bile Acids in Patients with Primary Sclerosing Cholangitis: A Phase 2, Randomized, Placebo-Controlled Trial - (11/15/18)
     
  532. AASLD: Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial - (11/15/18)
     
  533. AGE: More than 40% of HIV group has hepatic steatosis, regardless of age - Mark Mascolini (09/19/18)
     
  534. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  535. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  536. Mechanisms of NAFLD development and therapeutic strategies - (07/18/17)
     
  537. Time to step-up the fight against NAFLD - Comments from the Editors - (07/18/17)
     
  538. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data from a Large US Claims Database - (06/27/18)
     
  539. Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists - (06/15/18)
     
  540. EASL: The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/23/18)
     
  541. EASL: BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis: A Population Pharmacokinetics and Exposure-Response Analysis - (05/22/18)
     
  542. EASL: BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue, Reduces Fibrosis and PRO-C3 in a Mouse Model of Non-Alcoholic Steatohepatitis - (05/22/18)
     
  543. Evaluation of SOMAscan® as a Discovery Platform to Identify Noninvasive
    Protein Biomarkers for Diagnosis and Monitoring of NASH     - (05/21/18)
     
  544. The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/21/18)
     
  545. EASL: ACC Inhibitor Demonstrates Potent Antifibrotic Activity In Vitro and In Vivo - (05/17/18)
     
  546. EASL: Responsiveness of Controlled Attenuation Parameter and Its Correlation With Magnetic Resonance Imaging-Proton Density Fat Fraction in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (05/15/18)
     
  547. EASL: Combination of an FXR Agonist and an ACC Inhibitor Increases Antifibrotic Efficacy in Rodent Models of NASH - (05/15/18)
     
  548. EASL: Preliminary Efficacy and Safety of Acetyl-CoA Carboxylase Inhibitor GS-0976 in Patients With Compensated Cirrhosis Due To NASH - (05/15/18)
     
  549. EASL: Accurate Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH Using a Bayesian Machine Learning Approach - (05/15/18)
     
  550. EASL: The Conundrum of Cryptogenic Liver Disease [NASH] with Advanced Fibrosis: Poor Clinical Outcomes without Treatment Options - (05/15/18)
     
  551. EASL: Novel Characterization of the Gut Microbiome in Patients With NASH and Longitudinal Changes Associated With Histologic Improvement - (05/15/18)
     
  552. EASL: Mechanism for Hypertriglyceridemia and Effect of Fibrate Coadministration During Acetyl-CoA Carboxylase Inhibitor Treatment - (05/11/18)
     
  553. EASL: Characterization of Changes in Lipoprotein Profiles of Patients With Nonalcoholic Steatohepatitis Treated With the Acetyl-CoA Carboxylase Inhibitor GS-0976 - (05/09/18)
     
  554. EASL: An Integrated Safety Analysis of Phase 2 Studies of BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis - (04/25/18)
     
  555. EASL: Low-moderate alcohol use is associated with a lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) - (04/24/18)
     
  556. EASL: Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI - (04/24/18)
     
  557. EASL: Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/24/18)
     
  558. EASL: Substantial comorbidities and rising economic burden in real-world non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC): A large German claims database study - (04/23/18)
     
  559. EASL: NGM282 Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial - (04/20/18)
     
  560. EASL: NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/19/18)
     
  561. EASL: The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (04/19/18)
     
  562. EASL: NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis Markers at 6 Weeks - (04/19/18)
     
  563. EASL: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH) - (04/19/18)
     
  564. EASL: MGL-3196, a selective thyroid hormone receptor-beta agonist, significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study - (04/19/18)
     
  565. EASL: Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2b CENTAUR Study - (04/19/18)
     
  566. EASL: Proof-of-concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor (FXR) agonist (GS-9674) in NASH - (04/18/18)
     
  567. EASL: NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/18/18)
     
  568. NASH Future Therapies at Paris Hepatitis Conference Jan 2018 - (02/05/18)
     
  569. Merck NASH - (01/30/18)
     
  570. Fatty Liver, NASH in HIV - (01/30/18)
     
  571. Long Term Outcomes: Mortality and Causes of Death in NAFLD - (01/30/18)
     
  572. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus - (01/08/18)
     
  573. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention - (01/08/18)
     
  574. Fatty liver disease: turning the tide - (01/08/18)
     
  575. Nonalcoholic fatty liver disease.....liver enzymes-ALT/HIV/diet, exercise, metabolic syndrome, waist circumfrance, dysfunctional adipose tissue, diabetes, screening - (01/08/18)
     
  576. Fatty Liver, NASH - Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis - (01/02/17)
     
  577. Pharmacotherapy for NASH: Current and emerging - (01/02/17)
     
  578. Determinants of fibrosis progression and regression in NASH - (01/02/17)
     
  579. NAFLD: The evolving landscape - Editorial - (01/02/17)
     
  580. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  581. EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
     
  582. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  583. NAFLD AASLD Guidelines - The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases - (12/22/17)
     
  584. NAFLD and cancer: More cause for concern? - (12/21/17)
     
  585. Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD) / HIV & the Liver, Fatty Liver/NALFD - (12/20/17)
     
  586. The Global Epidemiology of Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis - (12/19/17)
     
  587. Burden of Illness Economic Model for Patients with Non-alcoholic Steatohepatitis (NASH) in the United States - (12/19/17)
     
  588. AASLD: Hepatocellular Carcinoma (HCC) in Patients with Non-Cirrhotic and Cirrhotic Nonalcoholic Fatty Liver Disease - (12/15/17)
     
  589. PPIs Increase NASH Risk - Microbiome & Fatty Liver: gut barrier dysfunction reported by speaker, leads to increased microbes into gut going to liver, increasing inflammation, and fatty liver - (12/11/17)
     
  590. HEP DART presentations 3 -7 Dec 2017 - (12/12/17)
     
  591. HEP-DART presentations 3 Dec - 7, 2017 - (12/11/17)
     
  592. NASH Globally - Pathways to combination therapies, biomarkers and outcomes - (12/11/17)
     
  593. Unmet needs in understanding pathogenesis and management of NAFLD and NASH - (12/11/17)
     
  594. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  595. AASLD: Cardiovascular risk in NAFLD- not an equal opportunity: implications for women's health - (11/29/17)
     
  596. Cirrhosis Predicts Bad Outcomes in NASH - (07/08/17)
     
  597. Cutting out the liver fat [NASH - better animal models needed] - Editorial - (07/08/17)
     
  598. EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
     
  599. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  600. AASLD: Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts early NASH and disease activity - (11/29/17)
     
  601. AASLD: NAFLD Debrief AASLD 2017 - (11/29/17)
     
  602. AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/29/17)
     
  603. AASLD: 4D Dynamic FDG-PET correlates with hepatic inflammation and steatosis in patients with non-alcoholic steatohepatitis - (11/29/17)
     
  604. AASLD: Multi-Biomarker Validation of MRI-PDFF- and MRE-Derived Treatment Response with BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)
     
  605. AASLD: Baseline Serum Pro-C3 Predicts Response to BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)
     
  606. AASLD: Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 "FIB-C3 Score" for Detection and Staging of Advanced Non-Alcoholic Fatty Liver Disease in a Large International Multi-Centre Patient Cohort - (11/20/17)
     
  607. AASLD: Prevalence and Clinical Characteristics of Nonalcoholic Fatty Liver Disease in Lean Subjects in Comparison with Overweight or Obese Individuals: A cross-sectional study - (11/20/17)
     
  608. AASLD: Advanced machine learning techniques to identify a panel of biomarkers that identify non-alcoholic steatohepatitis - (11/20/17)
     
  609. AASLD: Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test - (11/20/17)
     
  610. AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/20/17)
     
  611. AASLD: CM-101 a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model - (11/20/17)
     
  612. AASLD: Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis - (11/20/17)
     
  613. AASLD: The Long-Term Clinical Course of Histologically Advanced NAFLD. Impact of Fibrosis Severity on Major Clinical Outcomes. - An International and Multicenter Cohort Study - (11/17/17)
     
  614. AASLD: Natural History of Nonalcoholic Fatty Liver Disease in Children - (11/17/17)
     
  615. AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (10/28/17)
     
  616. AASLD: BMS-986036 (PEGylated FGF21) in Patients with Non-Alcoholic Steatohepatitis: A Phase 2 Study - (10/26/17)
     
  617. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  618. AASLD: Identification of Circulating MicroRNAs Altered by an Apoptosis Signal-Regulating Kinase 1 Inhibitor in a Fast-food Diet NAFLD Mouse Model - (11/14/17)
     
  619. AASLD: Plasma Metabolites for de Novo Lipogenesis and Pharmacodynamic Activity of Acetyl-CoA Carboxylase Inhibitor GS-0976 - (11/14/17)
     
  620. AASLD: Variability in Measurement of Hepatic Venous Pressure Gradient in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis: Results From a Randomized, Controlled Trial - (11/14/17)
     
  621. AASLD: Hepatic Venous Pressure Gradient Predicts Clinical Disease Progression in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (11/14/17)
     
  622. AASLD: Hepatic de Novo Lipogenesis Is Elevated in Patients With NASH Across the Spectrum of Disease Severity - (11/14/17)
     
  623. AASLD: Reductions in Hepatic Proton Density Fat Fraction Predict Histologic Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)
     
  624. AASLD: Reductions in Liver Stiffness by Magnetic Resonance Elastography Predict Fibrosis Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)
     
  625. AASLD: Serum Pro-C3 Is Associated With Hepatic Steatosis and Fibrosis, and Responsive to Changes in Steatosis in Patients With NASH - (11/13/17)
     
  626. AASLD: Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis - (11/13/17)
     
  627. AASLD: Prospective Validation of Hepatic Collagen Content for the Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH - (11/13/17)
     
  628. AASLD: Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) - (11/13/17)
     
  629. AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (11/13/17)
     
  630. AASLD: Combination of ASK1 and ACC Inhibitors Increases Efficacy in Rodent Models of NASH - (11/13/17)
     
  631. AASLD: Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamic Effects on de Novo Lipogenesis of the Acetyl-CoA Carboxylase Inhibitor GS-0976 in Healthy Volunteers - (11/13/17)
     
  632. AASLD: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function, and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH - (11/13/17)
     
  633. AASLD: norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study - (11/13/17)
     
  634. AASLD: Racial and Ethnic Disparities in Non-Alcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Meta-Analysis - (11/13/17)
     
  635. AASLD: Performance of liver stiffness by FibroScan in a Large Prospective Multicenter UK Study: Applicability, reliability, diagnostic performance and influence of the probe type and of steatosis on the liver stiffness measurement - (11/13/17)
     
  636. NASH: Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study - New trends on obesity and NAFLD in Asia / Lean-NASH - (10/03/17)
     
  637. Treatment of NAFLD with diet, physical activity and exercise - (09/26/17)
     
  638. EASL: Hepatic Fibrosis is Associated With Histological Activity in Non-alcoholic Steatohepatitis: an Analysis From a Large Database of Screening Biopsies in the CENTAUR Trial - (09/08/17)
     
  639. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter - (09/05/17)
     
  640. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD - (09/05/17)
     
  641. IAS: Fatty Liver in HIV+ at IAS - (08/05/17)
     
  642. Current and Future Therapeutic Approaches to NAFLD/NASH - (08/05/17)
     
  643. IAS: Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral therapy - (07/26/17)
     
  644. Bristol-Myers NASH drug hits primary endpoint in phase 2 - (07/22/17)
     
  645. Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial - (07/22/17)
     
  646. EASL: A NEW NON-INVASIVE DIAGNOSTIC SCORE TO MONITOR CHANGE IN DISEASE ACTIVITY AND PREDICT FIBROSIS EVOLUTION IN PATIENT WITH NASH - (07/17/17)
     
  647. EASL: Prospective Prevalence Study of Adult NAFLD/NASH Utilizing Multi-Modality Imaging Compared with Liver Biopsy - (07/17/17)
     
  648. EASL: Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies - (07/17/17)
     
  649. EASL: Simple non-invasive fibrosis scores identify patients with NAFLD who progress to advanced fibrosis/cirrhosis: evidence from a large cohort of patients with sequential liver biopsies. - (07/17/17)
     
  650. EASL: DNA Methylation Signatures in Blood Show Accelerated Epigenetic Aging in Patients with Nonalcoholic Steatohepatitis Compared to Healthy Controls - (07/07/17)
     
  651. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease - (07/07/17)
     
  652. EASL: Changes in Fibrosis, But Not the NAFLD Activity Score, Are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (07/06/17)
     
  653. EASL: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial - (07/05/17)
     
  654. EASL: INT 747 (obeticholic acid) fails to achieve goals in Japanese study for non-alcoholic steatohepatitis (NASH)- Intercept Pharma + Sumitomo - (07/05/17)
     
  655. EASL: Starting the battle to control non-alcoholic steatohepatitis [OCA FLINT Study] - Comment - (07/05/17)
     
  656. EASL: Nonalcoholic Steatohepatitis Drug Pipeline Overview - (07/05/17)
     
  657. EASL: Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis - (07/05/17)
     
  658. EASL: Elafibranor - (GFT505) NASH Treatment - GOLDEN 505 Study & Commentary - (07/05/17)
     
  659. EASL: Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes - (07/05/17)
     
  660. EASL: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Farnesoid X Receptor Agonist GS-9674, and Phenotypic Probe Substrates and Inhibitors/Inducers - (07/03/17)
     
  661. EASL: Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)
     
  662. EASL: Emerging Treatments for ASH & NASH - Rohit Loomba, MD / AASLD 2016 - (07/03/17)
     
  663. EASL: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Reduces Hepatic Steatosis and Liver Injury in a Murine Model of NASH - (07/03/17)
     
  664. EASL: Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multicenter Nonalcoholic Steatohepatitis Clinical Trial - (07/03/17)
     
  665. EASL: Apoptosis Signal-Regulating Kinase 1 Inhibition Reduces Liver Fibrosis and Apoptosis in an NLRP3 Mutant Model of NASH - (07/03/17)
     
  666. EASL: Impact of Weight Reduction on Serum Markers and Liver Histology Including Progression to Cirrhosis in Patients With Nonalcoholic Steatohepatitis and Bridging Fibrosis - (07/03/17)
     
  667. EASL: Impact of Modest Weight Reduction on Liver Histology, Portal Pressure, and Clinical Events in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (07/03/17)
     
  668. EASL: Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)
     
  669. Fatty Liver in HIV+ / HIV Research Politics, Aging - Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy - (07/03/17)
     
  670. IWCADRH: Clinical Implications of Nonalcoholic Fatty Liver Disease in Patients with HIV Infection - (06/23/17)